New checkpoint inhibitor on the blockResearchers at Austrian IMBA have identified a well-known co-factor of amino acid synthesis and monoamine neurotransmitter synthesis to play a prominent role in the development of autoimmunity and … more ➔
BIO-Europe: advanced therapies in focusGene and cell therapies, pediatric drugs, and formulation were just some hot topics discussed in a record number of B2B meetings at BIO-Europe in Copenhagen. more ➔
Dry AMD: Oxurion licences heparanase blockers from Beta TherapeuticsOxurion NV and Beta Therapeutics Inc have inked an R&D agreement aimed to develop new heparanase inhibitors to treat dry AMD. more ➔
Nanobots heading to eye deliveryGerman researchers have developed a drug delivery nanobot that can propel through the eye. more ➔
Argenx antibody kills AMLArgenx SE announced it achieved an overall response rate of 92% in patients with AML with its anti-TNFSF7 (CD70) antibody cusatuzumab. more ➔
Sanofi and Denali Therapeutics ink €1.125bn deal in neurology/inflammationSanofi has acquired the global commercialisation rights for two preclinical programmes from Denali Therapeutics. more ➔
ProQR in licence deal with Ionis PharmaceuticalsDutch ProQR NV has licensed global commercialisation rights to IONIS-RHO-2.5Rx (QR-1123) from Ionis Pharmaceuticals, to treat autosomal dominant retinitis pigmentosa (adRP) more ➔
Newron bags €40m EIB loanThe EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to €40m to support the development of the company’s late-stage pipeline. more ➔
TES Pharma presents new treatment approach towards AKI and NALFDTES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature. more ➔
MEPs vote for ban of single-use plasticsThe European Parliament has approved measures that could lead to a ban of the top 10 single use plastic products that contribute to marine littering by 2021. more ➔
